Skip to Content

Patient-Reported Outcomes of Belzutifan versus Everolimus in Patients with Previously Treated Advanced Renal Cell Carcinoma

In this MEDtalk, Dr. Thomas Powles discusses the quality of life data from the LITESPARK-005 study, a randomised phase III study comparing belzutifan with everolimus for heavily pre-treated patients with metastatic clear cell renal cancer.

Thomas Powles

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top